Editorial: Peptides against infectious diseases: from antimicrobial peptides to vaccines

Joanna Bojarska,Xiumin Wang,Mariusz Skwarczynski

DOI: https://doi.org/10.3389/fphar.2024.1522148

IF: 5.6

2024-12-12

Frontiers in Pharmacology

Abstract:Among other applications, they have been employed to detect, prevent, and treat infectious diseases. Peptides are used in diagnostic applications, imitating the molecular recognition properties of proteins for the detection of bacterial or viral infections, as antibiotics mimicking the function of natural antimicrobial peptides, and as crucial vaccine antigenic components and immunostimulators, to name a few applications. They are a very promising platform for drug and vaccine development (Skwarczynski and Toth, 2016;Wang and Li,2023). Nevertheless, peptides do have certain limitationsthey are easily biodegradable, break all Lipinski's rules, lack oral activity, and peptide antigens exhibit poor immunogenicity (Apostolopoulos et al., 2021;Apostolopoulos et al., 2022;Bucci et al., 2021). Thus, various strategies have been developed to overcome these shortcomings by structural modification or utilization of specialized formulations. This Research Topic, aimed to provide a forum for new studies and discussions on novel concepts, mechanisms, and applications in the field of peptide-based detection, prevention, and treatment of infectious diseases. It includes five original articles, one brief research report, and one review paper.Li et al. conducted a comprehensive review of the current research progress in the development and application of polyethylene glycol (PEG)-based therapeutic proteins and peptides. The authors discussed either the physicochemical properties or classification of PEG derivatives, keeping in mind the prospects of PEGylated peptides. In addition, they show opportunities for further innovations in this area.Cationic ultrashort lipopeptides are promising agents to fight multidrug-resistant bacteria. Hernández-Ortiz et al. demonstrated that anionic and neutral zwitterionic tripeptides exhibit antimicrobial and membrane-disrupting effects against inter alia Streptococcus pneumoniae and Streptococcus pyogenes. For their experiment, the researchers utilized newly designed C-terminal lipidated tripeptides with specific features (net charges ranging from -2 to +1) and a fatty amine conjugated to the C-terminal. Thus, the authors presented lipopeptides as appealing antimicrobial candidates with enhanced bioactivity and reduced toxicity for potential use in medical applications.Candida species are fungus species that have the ability to form biofilms that contribute to their pathogenicity and provide protection against antifungal drugs. Among these species, Candida glabrata is a prevalent yeast responsible for infections in humans, and is known for its ability to form biofilms. Madhuri et al. evaluated the combined effects of two highly promising naturally occurring antifungal lipopeptides named AF4 and AF5. They reported that these peptides exhibited an enhanced in vitro anti-biofilm effect when used alone or in combination with fluconazole.Melittin, an antimicrobial peptide derived from bee venom, is generally considered toxic and consequently lacks clinical utility. Nevertheless, modifications on its amino acid sequence through cyclization, dimerization, or truncation have been shown to reduce its toxicity. Matthyssen et al. substituted the three lysine residues with lysine homologs containing shorter side chains (such as ornithine, diaminobutyric acid, and diaminopropanoic acid) and dimerized melittin. They observed improved antimicrobial activity against Gram-negative bacteria, but no significant improvement in activity against Gram-positive bacteria. On the other hand, toxicity toward HEK293 and H4IIE cells was only slightly reduced. Furthermore, researchers suggested that more drastic modifications as well as encapsulation in nanocarriers, conjugation to other substances, and synergistic effects of melittin with antibiotics have the potential to reduce the effective dose of melittin to non-toxic levels.Acinetobacter baumanni is a highly drug-resistant pathogen, posing significant challenges in clinical treatment. Meng et al. conducted an evaluation of the synergistic antibacterial activity and additive effects of peptide antibiotics in combination with other antimicrobial agents against A. baumanni in both planktonic and biofilm forms in vitro. More specifically, the combination of polymyxins B and E together with imipenem act synergistically, while polymyxin E with rifampicin and bacitracin with imipenem or meropenem demonstrated additive effects against bacteria in planctonic form. In antibiofilm activity, synergistic activity was observed for combination of polymyxin B and E with azithromycin, while additive effect was confirmed for mixture of teicoplanin with tigecycline or rifampicin. The use of polymyxins along with carbapenems or azithromycin was suggested to represent an optimal therapeutic approach for A. baumannii infections.Suppressive antibiotic therapy is a valuable strategy to reduce infection progression in situations where alte -Abstract Truncated-

pharmacology & pharmacy